(Q24338918)

1

0 references

Michele Wezeman

2

0 references

Xiang Zhang

3

0 references

Pei Lin

4

0 references

Michael Wang

5

0 references

Jianfei Qian

6

0 references

Bo Wan

7

0 references

Long Yu

9

0 references

Qing Yi

Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma

10

0 references

language of work or name

English

0 references

publication date

September 2007

0 references

published in

Cancer Cell

0 references

volume

12

0 references

page(s)

252-65

0 references

issue

3

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

PI3K: downstream AKTion blocks apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

1 reference

7 January 2021

Identification of HLA-A*0201-restricted cytotoxic T-cell epitopes of Trypanosoma cruzi TcP2beta protein in HLA-transgenic mice and patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Evidence for C-reactive protein's role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with B-cell non-Hodgkin's lymphoma: correlation with extent of IL-6 expression and serum concentration

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Urinary albumin excretion and its relationship to C-reactive protein and proinflammatory cytokines in patients with cancer and febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

The major receptor for C-reactive protein on leukocytes is fcgamma receptor II.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Elevation of circulating IL-6 in patients with acute non-lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

C-reactive protein: a critical update

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer binding protein beta (C/EBP beta) and Rel p50.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021

Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2007.08.008

7 January 2021